SOLARA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 29/100 — Quality 33 · Momentum 19
| Share price | ₹570.15 |
| Market cap | ₹2,745 Cr |
| P/B ratio | 2.0 |
| ROE | -16.6% |
| ROCE | 6.1% |
| Book value | ₹287.12 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,369 Cr | ₹-7 Cr | 14.0% |
| 2025 | ₹1,284 Cr | ₹1 Cr | 16.0% |
| 2024 | ₹1,289 Cr | ₹-567 Cr | -7.0% |
| 2023 | ₹1,444 Cr | ₹-22 Cr | 9.0% |
| 2022 | ₹1,268 Cr | ₹-58 Cr | 6.0% |
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antih